Lipid Metabolism — MCQs

Lipid Metabolism Indian Medical PG Practice Questions and MCQs

Question 181: What is the desired ratio of total cholesterol to HDL cholesterol?

A. <7.5
B. <10
C. <3.5 (Correct Answer)
D. <4.5

Explanation: **Explanation:** The **Total Cholesterol/HDL ratio** (also known as the Castelli Index I) is a superior predictor of cardiovascular risk compared to total cholesterol alone. It reflects the balance between "bad" cholesterol (pro-atherogenic) and "good" cholesterol (anti-atherogenic). 1. **Why <3.5 is correct:** According to the American Heart Association (AHA) and standard biochemical guidelines, a ratio **below 3.5:1** is considered optimal or "ideal," indicating a very low risk of coronary artery disease (CAD). A ratio below 5.0 is generally considered acceptable for the average population, but for high-yield exam purposes, the "desired" or "target" clinical goal is <3.5. 2. **Analysis of Incorrect Options:** * **<4.5 (Option D):** While a ratio between 3.5 and 5.0 is considered "average risk," it is not the "ideal" or "desired" target for primary prevention. * **<7.5 and <10 (Options A & B):** These values represent high to very high cardiovascular risk. A ratio above 6.0 is associated with a significantly increased risk of myocardial infarction. **NEET-PG High-Yield Pearls:** * **HDL (High-Density Lipoprotein):** Known as the "Good Cholesterol" because it mediates **Reverse Cholesterol Transport** (carrying cholesterol from peripheral tissues back to the liver) via the enzyme **LCAT** (Lecithin-Cholesterol Acyltransferase). * **Friedewald Equation:** Used to calculate LDL. **LDL = Total Cholesterol – HDL – (Triglycerides/5)**. (Note: This is invalid if TG >400 mg/dL). * **Atherogenic Index:** The ratio of LDL/HDL is also used; the desired value is **<3.0**. * **Protective Factor:** HDL levels **>60 mg/dL** are considered a "negative" risk factor (it subtracts one risk factor from the total count).

Question 182: What is the important intermediate product of fatty acid biosynthesis?

A. Cholesterol
B. Malonyl CoA (Correct Answer)
C. Acetyl CoA
D. Thioesterases

Explanation: **Explanation:** Fatty acid biosynthesis (Lipogenesis) occurs primarily in the cytosol. The correct answer is **Malonyl CoA** because it is the dedicated building block and the first committed intermediate of the pathway. 1. **Why Malonyl CoA is correct:** The rate-limiting step of fatty acid synthesis is the carboxylation of Acetyl CoA to Malonyl CoA, catalyzed by the enzyme **Acetyl CoA Carboxylase (ACC)** (requires Biotin). Malonyl CoA serves as the 2-carbon donor for the Fatty Acid Synthase (FAS) complex. Crucially, Malonyl CoA also acts as a metabolic regulator by inhibiting **Carnitine Palmitoyltransferase-I (CPT-I)**, thereby preventing the newly synthesized fatty acids from entering the mitochondria for oxidation (preventing a futile cycle). 2. **Why other options are incorrect:** * **Cholesterol:** This is a complex lipid derived from Acetyl CoA via the HMG-CoA reductase pathway, not an intermediate of fatty acid synthesis. * **Acetyl CoA:** While it is the *starting substrate* (primer) for lipogenesis, it is not considered the specific intermediate product of the cycle itself. Most Acetyl CoA must be converted to Malonyl CoA to proceed. * **Thioesterases:** These are enzymes (not products) that catalyze the release of the finished palmitate chain from the Fatty Acid Synthase complex. **Clinical Pearls & High-Yield Facts:** * **Location:** Occurs in the "Liver, Lactating mammary gland, and Adipose tissue" (Mnemonic: **LLA**). * **Reductant:** **NADPH** is the essential co-factor, primarily supplied by the Hexose Monophosphate (HMP) Shunt. * **End Product:** The primary end product of the FAS complex is **Palmitate** (a 16-carbon saturated fatty acid). * **Citrate Shuttle:** Since Acetyl CoA cannot cross the mitochondrial membrane, it moves to the cytosol in the form of **Citrate**.

Question 183: NADPH produced in the extramitochondrial site primarily aids in the synthesis of which of the following biomolecules?

A. Ketone bodies
B. Steroids (Correct Answer)
C. Glycogen
D. None of the above

Explanation: **Explanation:** The correct answer is **Steroids**. NADPH (Nicotinamide Adenine Dinucleotide Phosphate) serves as the primary **reductive power** for biosynthetic pathways occurring in the cytosol (extramitochondrial site). **1. Why Steroids are correct:** The synthesis of cholesterol and its derivatives, such as steroid hormones, requires a significant amount of NADPH. It acts as a donor of electrons (reducing equivalents) in several steps, most notably the rate-limiting step catalyzed by **HMG-CoA reductase**. Other major pathways requiring NADPH include fatty acid synthesis and the maintenance of reduced glutathione for antioxidant defense. The primary source of this NADPH is the **Pentose Phosphate Pathway (Hexose Monophosphate Shunt)**. **2. Why other options are incorrect:** * **Ketone bodies:** Ketogenesis occurs primarily within the **mitochondria** of hepatocytes. It is a catabolic process involving the breakdown of Acetyl-CoA and does not require NADPH for its synthesis. * **Glycogen:** Glycogen synthesis (glycogenesis) is a process of glucose polymerization. It requires energy in the form of **UTP** (Uridine Triphosphate), not reductive power from NADPH. **Clinical Pearls for NEET-PG:** * **Sources of NADPH:** The HMP Shunt (via G6PD enzyme) and the Malic enzyme (converting malate to pyruvate) are the two most important sources. * **Tissues rich in HMP Shunt:** Adrenal cortex, gonads, and liver (due to active steroid and fatty acid synthesis) and RBCs (to maintain glutathione in a reduced state). * **Key mnemonic:** NADPH is for **"Building"** (Anabolism: Steroids, Fatty acids), while NADH is for **"Burning"** (Catabolism: ATP production in the Electron Transport Chain).

Question 184: What is the role of cholesterol present in LDL?

A. Represents primarily cholesterol that is being removed from peripheral cells.
B. Binds to a receptor and diffuses across the cell membrane.
C. On accumulation in the cell inhibits replenishment of LDL receptors. (Correct Answer)
D. When it enters a cell, it suppresses the activity of acyl-CoA: cholesterol acyltransferase (ACAT).

Explanation: ### Explanation The primary role of LDL (Low-Density Lipoprotein) is to transport cholesterol from the liver to peripheral tissues. This process is tightly regulated through a feedback mechanism known as the **Goldstein and Brown pathway**. **1. Why Option C is Correct:** When LDL binds to its specific Apo B-100 receptors, it is internalized via receptor-mediated endocytosis. Once inside the cell, the cholesterol is released. An increase in free intracellular cholesterol triggers a regulatory response to prevent "cholesterol overload." It **downregulates the synthesis of new LDL receptors** by inhibiting the transcription of the LDL receptor gene (via SREBP inhibition). This reduces further uptake of LDL from the blood. **2. Why the Other Options are Incorrect:** * **Option A:** This describes **HDL (High-Density Lipoprotein)**, which is involved in "Reverse Cholesterol Transport," moving cholesterol from peripheral cells back to the liver. * **Option B:** LDL does not "diffuse" across the membrane. It enters the cell through **clathrin-coated pits** via receptor-mediated endocytosis. * **Option D:** Intracellular cholesterol actually **activates ACAT** (Acyl-CoA: cholesterol acyltransferase). ACAT promotes the esterification of free cholesterol into cholesterol esters for storage, thereby reducing the toxic levels of free cholesterol within the cytoplasm. **Clinical Pearls for NEET-PG:** * **Rate-limiting step:** High intracellular cholesterol inhibits **HMG-CoA Reductase**, the rate-limiting enzyme of de novo cholesterol synthesis. * **Familial Hypercholesterolemia (Type IIa):** Caused by a genetic deficiency or defect in LDL receptors, leading to drastically elevated plasma LDL and premature atherosclerosis. * **Apo B-100:** The primary apoprotein found in LDL, which acts as the ligand for the LDL receptor.

Question 185: Which of the following fatty acids is produced by the fermentation of dietary fiber by colonic flora?

A. Palmitate
B. Butyrate (Correct Answer)
C. Oleate
D. Linoleate

Explanation: ### Explanation **Correct Answer: B. Butyrate** **Mechanism:** Dietary fibers (complex carbohydrates) are resistant to digestion in the human small intestine. When they reach the large intestine, they undergo anaerobic fermentation by the **colonic microbiota**. This process produces **Short-Chain Fatty Acids (SCFAs)**, primarily **Acetate (2C), Propionate (3C), and Butyrate (4C)**. Butyrate is the most clinically significant SCFA in the colon because it serves as the **primary energy source for colonocytes** (epithelial cells of the colon). It plays a vital role in maintaining mucosal integrity, regulating gene expression (via histone deacetylase inhibition), and exerting anti-inflammatory effects. --- ### Why the other options are incorrect: * **A. Palmitate (16:0):** This is a long-chain saturated fatty acid. It is the end-product of the **Fatty Acid Synthase (FAS)** multienzyme complex in the human cytosol, not a product of colonic fermentation. * **C. Oleate (18:1):** This is a monounsaturated fatty acid (MUFA) commonly found in olive oil. It is synthesized by the body via desaturation of stearate or obtained directly from the diet. * **D. Linoleate (18:2):** This is an **essential fatty acid** (Omega-6). Humans lack the enzymes (desaturases) to insert double bonds beyond carbon 9; therefore, it must be obtained from dietary plant oils and cannot be synthesized by colonic flora. --- ### High-Yield Clinical Pearls for NEET-PG: * **SCFA Ratio:** The typical molar ratio of SCFAs produced in the colon is approximately **60:20:20** (Acetate:Propionate:Butyrate). * **Propionate's Fate:** While butyrate is used locally by colonocytes, propionate travels to the liver where it serves as a substrate for **gluconeogenesis**. * **Cancer Protection:** Butyrate is hypothesized to reduce the risk of colorectal cancer by promoting apoptosis in mutated colon cells. * **Caloric Contribution:** SCFAs contribute roughly 5–10% of the total daily energy requirements in humans.

Question 186: In beta oxidation of palmitic acid, if the final product is acetoacetate, what is the net gain of ATP?

A. 21
B. 26 (Correct Answer)
C. 106
D. 129

Explanation: ### Explanation The net ATP yield of fatty acid oxidation depends on the final metabolic fate of the carbon units. **1. Why 26 is the Correct Answer:** * **Palmitic Acid (16C)** undergoes **7 cycles** of beta-oxidation. * **Products of 7 cycles:** 7 FADH₂, 7 NADH, and 8 Acetyl-CoA. * **ATP from Coenzymes:** * 7 FADH₂ × 1.5 ATP = 10.5 ATP * 7 NADH × 2.5 ATP = 17.5 ATP * Subtotal = 28 ATP * **The Twist:** Usually, Acetyl-CoA enters the TCA cycle. However, the question states the final product is **Acetoacetate** (a ketone body). In ketogenesis, Acetyl-CoA is converted to acetoacetate without entering the TCA cycle, meaning **no ATP is generated from the 8 Acetyl-CoA units.** * **Activation Cost:** 2 ATP equivalents are consumed to convert Palmitate to Palmitoyl-CoA. * **Net Yield:** (10.5 + 17.5) – 2 = **26 ATP.** **2. Analysis of Incorrect Options:** * **Option A (21):** Incorrect calculation, likely miscounting the number of beta-oxidation cycles. * **Option C (106):** This is the net yield of palmitate when it is **completely oxidized** to CO₂ and H₂O via the TCA cycle (108 gross - 2 activation). * **Option D (129):** This is the older calculation for complete oxidation (using 2 for FADH₂ and 3 for NADH). **3. High-Yield NEET-PG Pearls:** * **Location:** Beta-oxidation occurs in the mitochondria; Ketogenesis occurs only in the **liver mitochondria**. * **Rate-limiting step:** Carnitine Palmitoyltransferase-1 (CPT-1), inhibited by Malonyl-CoA. * **Ketogenesis:** Occurs during prolonged fasting or uncontrolled diabetes when OAA is depleted, diverting Acetyl-CoA away from the TCA cycle. * **Energy Math:** Always subtract 2 ATP for activation unless the question specifies "Palmitoyl-CoA" as the starting substrate.

Question 187: Which is the most potent HDL?

A. Pre-beta HDL (Correct Answer)
B. HDL-2
C. HDL-3
D. Discoidal HDL

Explanation: **Explanation:** The correct answer is **Pre-beta HDL**. **Why Pre-beta HDL is the most potent:** In the context of reverse cholesterol transport (RCT), "potency" refers to the efficiency of initiating cholesterol efflux from peripheral tissues. **Pre-beta HDL** is the smallest, most basic form of HDL, consisting primarily of **Apolipoprotein A-I (Apo A-I)** and phospholipids. Because it is "cholesterol-poor," it has the highest affinity for the **ABCA1 transporter**. This allows it to act as the primary and most potent acceptor of free cholesterol from macrophages and peripheral cells, initiating the protective anti-atherogenic process. **Analysis of Incorrect Options:** * **HDL-2:** This is a large, lipid-rich, mature spherical HDL particle. While it is highly protective and its levels correlate inversely with CHD risk, it is a "product" of cholesterol accumulation rather than the initial potent acceptor. * **HDL-3:** This is a smaller, denser spherical HDL. It is formed from discoidal HDL via the action of the LCAT enzyme. It is less potent than pre-beta HDL in initiating efflux. * **Discoidal HDL:** Also known as nascent HDL, these are slightly more organized than pre-beta HDL but represent a transitional stage. Pre-beta HDL remains the most kinetically active form for initial cholesterol uptake. **High-Yield Clinical Pearls for NEET-PG:** * **Reverse Cholesterol Transport (RCT):** The process of moving cholesterol from peripheral tissues to the liver for excretion. * **Rate-limiting step:** The interaction between Apo A-I (on pre-beta HDL) and the **ABCA1 receptor**. * **LCAT (Lecithin-Cholesterol Acyltransferase):** The enzyme that converts free cholesterol into cholesterol esters, transforming nascent/pre-beta HDL into mature spherical HDL (HDL3 and HDL2). * **CETP (Cholesterol Ester Transfer Protein):** Mediates the exchange of cholesterol esters from HDL for triglycerides from VLDL/LDL.

Question 188: Which of the following is NOT true about Docosahexaenoic acid?

A. It is found in the highest concentration in the retina, cerebral cortex, and sperms.
B. It is needed for the development of the fetal brain and retina.
C. It is supplied transplacentally and through breast milk.
D. It can be synthesized in the body from linoleic acid. (Correct Answer)

Explanation: **Explanation:** **1. Why Option D is the Correct Answer (The Concept):** Docosahexaenoic acid (DHA) is an **Omega-3 (ω-3)** fatty acid. It is synthesized in the body from **α-Linolenic acid (ALA)**, which is the parent 18-carbon ω-3 fatty acid. In contrast, **Linoleic acid** is the parent **Omega-6 (ω-6)** fatty acid and serves as the precursor for Arachidonic acid. Since ω-3 and ω-6 pathways are distinct and cannot be interconverted in humans, DHA cannot be synthesized from linoleic acid. **2. Analysis of Other Options:** * **Option A:** DHA is a major structural component of phospholipids in cellular membranes. It is found in exceptionally high concentrations in the **retina** (photoreceptor outer segments), **cerebral cortex** (synaptic membranes), and **sperms**, where it maintains membrane fluidity and signaling. * **Option B:** DHA is critical for the structural and functional development of the **fetal central nervous system** and visual acuity. Deficiencies during pregnancy can lead to impaired cognitive and visual outcomes. * **Option C:** Since the fetus has limited capacity to synthesize DHA from ALA, it relies on **active transplacental transport** during the third trimester. Postnatally, **breast milk** is the primary source, as most standard cow-milk formulas historically lacked DHA (though many are now fortified). **Clinical Pearls for NEET-PG:** * **Essential Fatty Acids (EFA):** Only Linoleic acid and α-Linolenic acid are "true" EFAs because humans lack Δ12 and Δ15 desaturases. * **DHA Structure:** It is a 22-carbon chain with 6 double bonds (C22:6, ω-3). * **Zellweger Syndrome:** A peroxisomal disorder where DHA synthesis is impaired (the final β-oxidation step of DHA synthesis occurs in peroxisomes), leading to severe neurological deficits.

Question 189: Alpha oxidation does not generate energy but is important for the brain. In which cell organelle does alpha oxidation take place?

A. Peroxisomes (Correct Answer)
B. Nucleoli
C. Mitochondria
D. Nucleus

Explanation: **Explanation:** **Alpha-oxidation** is a specialized metabolic pathway required for the breakdown of **branched-chain fatty acids**, most notably **phytanic acid** (derived from chlorophyll in the diet). Unlike beta-oxidation, which occurs in the mitochondria, alpha-oxidation takes place within the **peroxisomes**. 1. **Why Peroxisomes are correct:** Branched-chain fatty acids have a methyl group at the beta-carbon, which sterically hinders the enzymes of beta-oxidation. Alpha-oxidation removes one carbon atom at a time from the carboxyl end (the alpha-carbon), bypassing this blockage. This process is vital for brain development and myelin maintenance. 2. **Why other options are incorrect:** * **Mitochondria:** This is the primary site for **beta-oxidation** of long-chain fatty acids and the TCA cycle. * **Nucleus and Nucleoli:** These organelles are involved in genetic material storage (DNA), transcription (RNA synthesis), and ribosome biogenesis; they do not participate in lipid catabolism. **High-Yield Clinical Pearls for NEET-PG:** * **Refsum Disease:** A rare autosomal recessive disorder caused by a deficiency of the peroxisomal enzyme **Phytanoyl-CoA hydroxylase**. This leads to the toxic accumulation of phytanic acid in tissues. * **Clinical Presentation:** Characterized by the triad of **retinitis pigmentosa, peripheral neuropathy, and cerebellar ataxia**. * **Key Feature:** Unlike beta-oxidation, alpha-oxidation **does not require CoA** activation and **does not generate ATP**. * **Zellweger Syndrome:** A generalized peroxisomal biogenesis disorder that also affects alpha and very-long-chain fatty acid (VLCFA) oxidation.

Question 190: Primary hypercholesterolemia is classified as which type according to Fredrickson's classification?

A. Type I
B. Type IIa (Correct Answer)
C. Type IIb
D. Type III

Explanation: **Explanation:** Fredrickson’s classification (WHO classification) of hyperlipoproteinemias is based on the specific lipoprotein pattern observed in the plasma. **Why Type IIa is correct:** **Type IIa (Familial Hypercholesterolemia)** is characterized by a deficiency in **LDL receptors**, leading to an isolated elevation of **Low-Density Lipoprotein (LDL)**. Since LDL is the primary carrier of cholesterol, this results in significantly high serum cholesterol levels with normal triglycerides. Clinically, this presents with xanthelasma and tendon xanthomas. **Analysis of Incorrect Options:** * **Type I (Familial Chylomicronemia):** Caused by a deficiency of Lipoprotein Lipase (LPL) or Apo C-II. It results in elevated **Chylomicrons**, leading to severe hypertriglyceridemia, not primary hypercholesterolemia. * **Type IIb (Combined Hyperlipidemia):** Characterized by elevations in both **LDL and VLDL**. This results in high levels of both cholesterol and triglycerides. * **Type III (Dysbetalipoproteinemia):** Caused by Apo E deficiency, leading to the accumulation of **IDL (Chylomicron remnants)**. It typically presents with palmar xanthomas and elevations in both cholesterol and triglycerides. **High-Yield Pearls for NEET-PG:** * **Type IIa:** Defective LDL receptor; isolated high Cholesterol. * **Type IV:** Most common type; elevated **VLDL** (Endogenous hypertriglyceridemia). * **Type I:** Associated with eruptive xanthomas and acute pancreatitis. * **Apo B-100:** The primary apolipoprotein associated with LDL (elevated in Type II). * **Statins:** The first-line treatment for Type IIa to upregulate LDL receptors.

Practice by Chapter

Lipid Classification and Chemistry

Practice Questions

Fatty Acid Oxidation

Practice Questions

Ketone Body Metabolism

Practice Questions

Fatty Acid Synthesis

Practice Questions

Metabolism of Triacylglycerols

Practice Questions

Phospholipid Metabolism

Practice Questions

Cholesterol Metabolism and Biosynthesis

Practice Questions

Bile Acids and Bile Salts

Practice Questions

Lipoprotein Metabolism and Transport

Practice Questions

Dyslipidemias and Atherosclerosis

Practice Questions

Prostaglandins and Eicosanoids

Practice Questions

Fatty Liver and Lipotropic Factors

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free